The role of the infectious agents in the pathogenesis and evolution of atherosclerosis

Annali Italiani di Medicina Interna

Volumn 19, Issue 4, 2004, Pages 249-261

  Blasi, Claudio ^a  

^a ASL Roma B   (Italy)

Author keywords

Atherosclerosis; Chlamydia pneumoniae; Cytomegalovirus; Heat shock protein; Infectious agents

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL VACCINE; HEAT SHOCK PROTEIN;

ARTERIOSCLEROSIS; BACTERIAL INFECTION; BIOSYNTHESIS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; ENDOTHELIUM CELL; HUMAN; IMMUNOLOGY; INFECTION; METABOLISM; MICROBIOLOGY; REVIEW; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; ARTERIOSCLEROSIS; BACTERIAL VACCINES; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIALS; ENDOTHELIAL CELLS; HEAT-SHOCK PROTEINS; HUMANS; INFECTION; TREATMENT OUTCOME;

EID: 14544267746     PISSN: 03939340     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (126)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9.
2. Sawayama Y, Tatsukawa M, Okada K, et al. Association of Chlamydia pneumoniae antibody with the cholesterol-lowering effect of statins. Atherosclerosis 2003; 171: 281-5.
3. Prasad A, Zhu J, Halcox JP, et al. Predisposition to atherosclerosis by infections. Role of endothelial dysfunction. Circulation 2002; 106: 184-90.
4. Nedeljkovic ZS, Gokce N, Loscalzo J. Mechanisms of oxidative stress and vascular dysfunction. Postgrad Med J 2003; 79: 195-200.
5. Poredos P. Endothelial dysfunction and cardiovascular disease. Pathophysiol Haemost Thromb 2002; 32: 274-7.
6. Wheatcroft SB, Williams IL, Shah AM, Kearney MT. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med 2003; 20: 255-68.
7. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction. A marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23: 168-75.
8. Wick G, Knoflach M, Xu Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol 2004; 22: 361-403.
9. Osler W. Diseases of the arteries. In: Osler W, ed. Modern medicine: its theory and practice. Philadelphia, PA: Lea & Febiger, 1908: 426-47.
10. Gibbon RV. Germs, Dr. Billings, and the theory of focal infection. Clin Infect Dis 1998; 27: 627-33.
11. Benditt EP, Benditt JM. Evidence of a monoclonal origin of human atherosclerotic plaques. Proc Natl Acad Sci USA 1973; 70: 1753-66.
12. Fabricant CG, Fabricant J. Atherosclerosis induced by infection with Marek's disease herpesvirus in chickens. Am Heart J 1999; 138: S465-S468.
13. Saikku P, Leinonen M, Mattila K, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2: 983-6.
14. Nicoletti A, Caligiuri G, Paulsson G, Hansson GK. Functionality of specific immunity in atherosclerosis. Am Heart J 1999; 138: S438-S443.
15. Mayr M, Kiechl S, Willeit J, Wick G, Xu Q. Infections, immunity and atherosclerosis: associations of antibodies to Chlamydia pneumoniae, Helicobacter pylori, and Cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis. Circulation 2000; 102: 833-9.
16. Biondi-Zoccai GGL, Abbate A, Liuzzo G, Biasucci LM. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol 2003; 41: 1071-7.
17. Epstein SE, Zhu J, Burnett MS, Zhou YF, Vercellotti G, Hajjar D. Infection and atherosclerosis: potential roles of pathogen burden and molecular mimicry. Arterioscler Thromb Vasc Biol 2000; 20: 1417-20.
18. O'Connor S, Taylor C, Campbell LA, Epstein S, Libby P. Potential infectious etiologies of atherosclerosis: a multifactorial prospective. Emerg Infect Dis 2001; 7: 780-7.
19. Nicholson AC, Hajjar DP. Viral activation of the coagulation cascade. Am Heart J 1999; 138: S461-S464.
20. Melnick JL, Hu C, Burek J, Adam E, De Bakey ME. Cytomegalovirus DNA in arterial walls of patients with atherosclerosis. J Med Virol 1994; 42: 170-4.
21. Nieto J. Viruses and atherosclerosis: a critical review of the epidemiologic evidence. Am Heart J 1999; 138: S443-S460.
22. Zhou YF, Shou M, Guetta E, et al. Cytomegalovirus infection of rats increases the neointimal response to vascular injury without consistent evidence of direct infection of the vascular wall. Circulation 1999; 100: 1569-75.
23. Sorlie PD, Nieto J, Adam E, Folsom AR, Shahar E, Massing M. A prospective study of Cytomegalovirus, herpes simplex virus 1, and coronary heart disease. Arch Intern Med 2000; 160: 2027-32.
24. Stöllberger C, Finsterer J. Atherosclerosis: infection-induced involvement of mitochondrial chaperonins. Lancet 2003; 362: 1949-50.
25. Bruggeman C. Cytomegalovirus is involved in vascular pathology. Am Heart J 1999; 138: S473-S475.
26. Jarvis M, Nelson J. Human Cytomegalovirus persistence and latency in endothelial cells and macrophages. Curr Opin Microbiol 2002; 5: 403-7.
27. Epstein SE, Zhou YF, Zhu J. Potential role of Cytomegalovirus in the pathogenesis of restenosis and atherosclerosis. Am Heart J 1999; 138: S476-S478.
28. Bason C, Corrocher R, Lunardi C, et al. Interaction of antibodies against Cytomegalovirus with heat-shock protein 60 in pathogenesis of atherosclerosis. Lancet 2003; 362: 1971-7.
29. Zhou YF, Leon MB, Waclawiw MA, et al. Association between prior Cytomegalovirus infection and risk of restenosis after coronary atherectomy. N Engl J Med 1996; 335: 624-30.
30. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261: 3561-6.
31. Potena L, Grigioni F, Ortolani P, et al. Relevance of Cytomegalovirus infection and coronary-artery remodeling in the first year after heart transplantation: a prospective three-dimensional intravascular ultrasound study. Transplantation 2003; 75: 839-43.
32. Hosenpud JD. Coronary artery disease after heart transplantation and its relation to Cytomegalovirus. Am Heart J 1999; 138: S469-S472.
33. Valantine HA. Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant "atheroma". Transplantation 2003; 76: 891-9.
34. Rupprecht HJ, Blankenberg S, Bickel C, et al. Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. Circulation 2001; 104: 25-31.
35. Ishizaka N, Ishizaka Y, Takahashi E, et al. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet 2002; 359: 133-5.
36. Roivainen M. Enteroviruses and myocardial infarction. Am Heart J 1999; 138: S479-S483.
37. Kusters JG, Kuipers EJ. Helicobacter and atherosclerosis. Am Heart J 1999; 138: S523-S527.
38. Mendall MA, Goggin PM, Molineaux N, et al. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J 1994; 71: 437-9.
39. Gabrielli M, Santoliquido A, Cremonini F, et al. CagA-positive cytotoxic H. pylori strains as a link between plaque instability and atherosclerotic stroke. Eur Heart J 2004; 25: 64-8.
40. Zhu J, Katz RJ, Quyyumi AA, et al. Association of serum antibodies to heat-shock protein 65 with coronary calcification levels. Suggestion of pathogen-triggered autoimmunity in early atherosclerosis. Circulation 2004; 109: 36-41.
41. Mayr M, Kiechl S, Mendall MA, et al. Increased risk of atherosclerosis is confined to CagA-positive Helicobacter pylori strains: prospective results from the Bruneck study. Stroke 2003; 34: 610-5.
42. Beck JD, Pankow J, Tyroler HA, Offenbacher S. Dental infections and atherosclerosis. Am Heart J 1999; 138: S528-S533.
43. Wick G, Perschinka H, Xu Q. Autoimmunity and atherosclerosis. Am Heart J 1999; 138: S444-S449.
44. Higgins JP, Higgins JA, Higgins PM, Ahuja S, Higgins DL. Chlamydia pneumoniae and coronary artery disease: legitimized linkages? Expert Rev Cardiovasc Ther 2003; 1: 367-84.
45. Boland JP. Chlamydia pneumoniae and cardiovascular disease: current status. W V Med J 2000; 96: 458.
46. Kuo CC, Jackson LA, Campbell LA, Grayston JT. Chlamydia pneumoniae (TWAR). Clin Microbiol Rev 1995; 8: 451-61.
47. Kalayoglu MV, Libby P, Byrne GI. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA 2002; 288: 2724-31.
48. Meier CR. Antibiotics in the prevention and treatment of coronary heart disease. J Infect Dis 2000; 81 (Suppl 3): S558-S562.
49. Kalayoglu MV. Chlamydial heat shock protein 60 and lipopolysaccharide: potential virulence determinants in atherogenesis. Curr Drugs Targets Inflamm Allergy 2002; 1: 249-55.
50. Stratton CW, Sriram S. Association of Chlamydia pneumoniae with central nervous system disease. Microbes Infect 2003; 5: 1249-53.
51. Tasaki N, Nakajima M, Yamamoto H, et al. Influence of Chlamydia pneumoniae infection on aortic stiffness in healthy young men. Atherosclerosis 2003; 171: 117-22.
52. Campbell LA, Kuo CC. Chlamydia pneumoniae and atherosclerosis. Semin Respir Infect 2003; 18: 48-54.
53. Lindholt JS, Stovring J, Andersen PL, Henneberg EW, Ostergaard L. A review of macrolide treatment of atherosclerosis and abdominal aortic aneurysms. Curr Drug Targets Infect Disord 2003; 3: 55-63.
54. Siscovick DS, Schwartz S, Caps M, Wang SP, Grayston JT. Chlamydia pneumoniae and atherosclerotic risk in populations: the role of seroepidemiology. J Infect Dis 2000; 81 (Suppl 3): S417-S420.
55. Zairis MN, Papadaki OA, Paraskevi K. Serologic markers of persistent Chlamydia pneumoniae infection and long-term prognosis after successful coronary stenting. Am Heart J 2003; 146: 1082-9.
56. Rosenfeld ME, Blessing E, Lin TM, Moazed TC, Campbell LA. Chlamydia, inflammation and atherogenesis. J Infect Dis 2000; 81 (Suppl 3): S492-S496.
57. Hu H, Pierce GN, Zhong G. The atherogenic effects of Chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest 1999; 103: 747-53.
58. Muhlestein JB. Chlamydia pneumoniae-induced atherosclerosis in a rabbit model. J Infect Dis 2000; 181 (Suppl 3): 505-7.
59. Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998; 97: 633-6.
60. Fong IW, Chiu B, Viira E, Jang D, Mahony JB. Influence of clarithromycin on early atherosclerotic lesions after Chlamydia pneumoniae infection in a rabbit model. Antimicrob Agents Chemother 2002; 46: 2321-6.
61. Stille W, Dittmann R. Atherosclerosis as a sequela of chronic Chlamydia pneumonia infection. Herz 1998; 23: 185-92.
62. Kalayoglu MV, Hoerneman B, LaVerda D, Morrison SG, Morrison RP, Byrne GI. Cellular oxidation of low-density lipoprotein by Chlamydia pneumoniae. J Infect Dis 1999; 180: 780-90.
63. Kalayoglu MV, Morrison RP, Morrison SG, Yuan Y, Byrne GI. Chlamydial virulence determinants in atherogenesis: the role of chlamydial lipopolysaccharide and heat shock protein 60 in macrophage-lipoprotein interactions. J Infect Dis 2000; 81 (Suppl 3): S483-S489.
64. Ludewig B, Zinkernagel RM, Hengartner H. Arterial inflammation and atherosclerosis. Trends Cardiovasc Med 2002; 12: 154-9.
65. Taylor-Robinson D, Thomas BJ. Chlamydia pneumoniae in atherosclerotic tissue. J Infect Dis 2000; 81 (Suppl 3): S437-S440.
66. Kuo CC, Campbell LA. Detection of Chlamydia pneumoniae in arterial tissues. J Infect Dis 2000; 81 (Suppl 3): S432-S435.
67. Muhlestein JB. Antibiotic treatment of atherosclerosis. Curr Opin Lipidol 2003; 14: 605-14.
68. Ciervo A, Petrucca A, Cassone A. Identification and quantification of Chlamydia pneumoniae in human atherosclerotic plaques by LightCycler real-time-PCR. Mol Cell Probes 2003; 17: 107-11.
69. Ramirez JA. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/ Atherosclerosis Study Group. Ann Intern Med 1996; 125: 979-82.
70. Belland RJ, Ouellette SP, Gieffers J, Byrne GI. Chlamydia pneumoniae and atherosclerosis. Cell Microbiol 2004; 6: 117-27.
71. Gaydos CA. Growth in vascular cells and cytokine production by Chlamydia pneumoniae. J Infect Dis 2000; 81 (Suppl 3): S473-S478.
72. Kälvegren H, Majeed M, Bengtsson T. Chlamydia pneumoniae binds to platelets and triggers P-selectin expression and aggregation. A causal role in cardiovascular disease? Arterioscler Thromb Vasc Biol 2003; 23: 1677-83.
73. Epstein SE, Zhou YF, Zhu J. Infection and atherosclerosis. Emerging mechanistic paradigms. Circulation 1999; 100: E20-E28.
74. Lopes-Virella MF, Virella G. The role of immune and inflammatory processes in the development of macrovascular disease in diabetes. Front Biosci 2003; 8: S750-S768.
75. Summersgill JT, Molestina RE, Miller RD, Ramirez JA. Interactions of Chlamydia pneumoniae with human endothelial cells. J Infect Dis 2000; 81 (Suppl 3): S479-S482.
76. Baer JT, du Laney TV, Wyrick PB, et al. Nuclear factor-κB activation in endothelium by Chlamydia pneumoniae without active infection. J Infect Dis 2003; 188: 1094-7.
77. Wong YK, Gallagher PJ, Ward ME. Chlamydia pneumoniae and atherosclerosis. Heart 1999; 81: 232-8.
78. Hortovànyi E, Illyés G, Kàdàr A. Early atherosclerosis and Chlamydia pneumoniae infection in the coronary arteries. Pathol Oncol Res 2003; 9: 42-6.
79. Choi EY, Dongsoo K, Hong BK, et al. Upregulation of extracellular matrix metalloproteinase inducer (EMMPRIN) and gelatinases in human atherosclerosis infected with Chlamydia pneumoniae: the potential role of Chlamydia pneumoniae infection in the progression of atherosclerosis. Exp Mol Med 2002; 34: 391-400.
80. Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-α and matrix metalloproteinase expression. Circulation 1998; 98: 300-7.
81. Cornelussen RN, Vanagt WY, Prinzen FW, Snoeckx LH. Proteins involvement in salvage of the myocardium. Adv Exp Med Biol 2003; 543: 277-91.
82. Zügel U, Kaufman SH. Role of heat shock proteins in protection from and pathogenesis of infectious diseases. Clin Microbiol Rev 1999; 12: 19-39.
83. Gleimer M, Parham P. Stress management: MHC class I and class I-like molecules as reporters of cellular stress. Immunity 2003; 19: 469-77.
84. Hirono S, Dibrov E, Hurtado C, Kostenuk A, Ducas R, Pierce GN. Chlamydia pneumoniae stimulates proliferation of vascular smooth muscle cells through induction of endogenous heat shock protein 60. Circ Res 2003; 93: 710-6.
85. Asea A. Chaperokine-induced signal transduction pathways. Exerc Immunol Rev 2003; 9: 25-33.
86. Lamb DJ, El-Sankary W, Ferns GA. Molecular mimicry in atherosclerosis: a role of heat shock proteins in immunization. Atherosclerosis 2003; 167: 177-85.
87. Kol A, Lichtman AH, Finberg RW, Libby P, Kurt-Jones EA. Cutting edge: heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP 60 activation of mononuclear cells. J Immunol 2000; 164: 13-7.
88. Campisi J, Leem TH, Fleshner M. Stress-induced extracellular Hsp 72 is a functional significant danger signal to the immune system. Cell Stress Chaperones 2003; 8: 272-86.
89. Mayr M, Metzler B, Kiechl S, et al. Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae. Circulation 1999; 99: 1560-6.
90. Pockley AG. Heat shock proteins, inflammation, and cardiovascular disease. Circulation 2002; 105: 1012-7.
91. Knoflach M, Kiechl S, Kind M, et al. Cardiovascular risk factors and atherosclerosis in young males. ARMY study (Atherosclerosis Risk-Factors in Male Youngsters). Circulation 2003; 108: 1064-9.
92. nullT cells in patients with acute coronary syndromes. Circulation 2004; 109: 1230-5.
93. Schett G, Xu Q, Amberger A, et al. Autoantibodies against heat shock protein 60 mediate endothelial cytotoxicity. J Clin Invest 1995; 96: 2569-77.
94. Tousoulis D, Davies G, Stefanadis G, Toutouzas P, Ambrose JA. Inflammatory and thrombotic mechanisms in coronary atherosclerosis. Heart 2003; 89: 993-7.
95. DeGraba TJ. The role of inflammation in atherosclerosis. Adv Neurol 2003; 92: 29-42.
96. Biasucci LM, Liuzzo G, Ciervo A, et al. Antibody response to chlamydial heat shock protein 60 is strongly associated with acute coronary syndromes. Circulation 2003; 107: 3015-7.
97. Tiran A, Tio RA, Ossewaarde JM. Coronary angioplasty induces rise in Chlamydia pneumoniae-specific antibodies. J Clin Microbiol 1999; 37: 1013-7.
98. Gorge J, Greenberg S, Barshack I, et al. Immunity to heat shock protein 65 - an additional determinant in intimal thickening. Atherosclerosis 2003; 168: 33-8.
99. Shi Y, Tokunaga O. Chlamydia pneumoniae and multiple infections in the aorta contribute to atherosclerosis. Pathol Int 2002; 52: 755-63.
100. Wick G, Schett G, Amberger A, Kleindienst R, Xu Q. Is atherosclerosis an immunologically mediated disease? Immunol Today 1995; 16: 27-39.
101. Balin BJ, Gerard HC, Arking EJ, et al. Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain. Med Microbiol Immunol 1998; 187: 23-42.
102. Gilden DH. Chlamydia a role for multiple sclerosis or more confusion? Ann Neurol 1999; 46: 6-14.
103. Gérard HC, Wang GF, Balin BJ, Schumacher HR, Hudson AP. Frequency of apolipoprotein E (APOE) allele types in patients with Chlamydia-associated arthritis and other arthritides. Microb Pathog 1999; 26: 35-43.
104. Ewald PW, Cochran GM. Chlamydia pneumoniae and cardiovascular disease: an evolutionary perspective on infectious causation and antibiotic treatment. J Infect Dis 2000; 81 (Suppl 3): S394-S401.
105. Sriram S, Stratton CW, Yao SY, et al. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Ann Neurol 1999; 46: 6-14.
106. Beatty WL, Morison RP, Byrne GI. Persistent Chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev 1994; 58: 686-99.
107. Higgins JP. Chlamydia pneumoniae and coronary artery disease: the antibiotic trials. Mayo Clin Proc 2003; 78: 321-32.
108. Fong IW. Value of animal models for Chlamydia pneumoniae-related atherosclerosis. Am Heart J 1999; 138: S512-S513.
109. Gupta S, Leatham EW, Carrington D. Elevated Chlamydia pneumoniae antibodies, cardiovascular events and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404-7.
110. Grayston JT. Antibiotic treatment of atherosclerotic cardiovascular disease. Circulation 2003; 107: 1228-30.
111. Cercek B, Shah PK, Noc M, et al. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet 2003; 361: 809-13.
112. Grayston JT. Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. J Infect Dis 2000; 81 (Suppl 3): S402-S410.
113. Anderson JL, Muhlestein JB, Carlquist J, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serologic evidence for Chlamydia pneumoniae infection: the Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 1999; 99: 1540-7.
114. Meier CR, Derby LE, Jick SS, Vasilakis C, Jick H. Antibiotics and risk of subsequent first-time myocardial infarction. JAMA 1999; 281: 427-31.
115. Liuba P, Persson J, Luoma J, Ylä-Herttuala S, Pesonen E. Acute infection in children are accompanied by oxidative modification of LDL and decrease of HDL cholesterol, and are followed by thickening of carotid intima-media. Eur Heart J 2003; 24: 515-21.
116. Stephens RS. Chlamydial genomics and vaccine antigen discovery. J Infect Dis 2000; 81 (Suppl 3): S521-S523.
117. Shirai M, Hirakawa H, Ouchi K, et al. Comparison of outer membrane protein genes omp and pmp in the whole genoma sequences of Chlamydia pneumoniae isolates from Japan and the United States. J Infect Dis 2000; 81 (Suppl 3): S524-S528.
118. Brunham RC, Zhang DJ, Yang X, McClarty GM. The potential for vaccine development against Chlamydia infection and disease. J Infect Dis 2000; 81 (Suppl 3): S538-S543.
119. Slepenkin A, Motin V, de la Maza LM, Peterson EM. Temporal expression of type III secretion genes of Chlamydia pneumoniae. Infect Immun 2003; 71: 2555-62.
120. Brunham RC, Zhang DJ. Transgene as vaccine for chlamydia. Am Heart J 1999; 138: S519-S522.
121. Fong IW. Antibiotics effects in a rabbit model of Chlamydia pneumoniae-induced atherosclerosis. J Infect Dis 2000; 181 (Suppl 3): S514-S518.
122. Harats D, Yacov N, Gilburd B, Schoenfeld Y, George J. Oral tolerance with heat shock protein 65 attenuates Mycobacterium tuberculosis-induced and high-fat-diet-driven atherosclerotic lesions. J Am Coll Cardiol 2002; 40: 1333-8.
123. Maron R, Sukhova G, Faria AM, et al. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation 2002; 106: 1708-15.
124. Moling O, Mian P. Induction of oral tolerance as treatment or prevention of chronic diseases associated with Chlamydia pneumoniae infection - hypothesis. Med Sci Monit 2003; 9: HY15-HY18.
125. Birk OS, Gur SL, Elias D, et al. The 60-kDa heat shock protein modulates allograft rejection. Proc Natl Acad Sci USA 1999; 96: 5159-63.
126. Leinonen M. Chlamydia pneumoniae and other risk factors for atherosclerosis. J Infect Dis 2000; 81 (Suppl 3): S414-S416.